Table 2.

Overview of trial patient baseline characteristics.

Potential matching variable	Available and presented consistently in BOLT and ERIVANCE?	Distribution differs between BOLT and ERIVANCE?	Is the variable prognostic?
Age	Yes	No  (i) BOLT = 64.6 (mean)   (ii) ERIVANCE = 61.4 (mean)	BOLT exploratory analysis suggests prognostic [7], but Chang et al. [25] suggest nonsignificant relationship with ORR
Sex	Yes	No  (i) BOLT = 57.6% (male)   (ii) ERIVANCE = 55.6% (male)	Unknown
Race	Yes	No  (i) BOLT = 89.4% white, 10.6% other  (ii) ERIVANCE = 100% white	Unknown
ECOG status	Yes	No  (i) BOLT:    (a) ECOG status 0 = 66.7%   (b) ECOG status 1 = 24.2%   (c) ECOG status 2 = 6.1%  (ii) ERIVANCE    (a) ECOG status 0 = 76.2%    (b) ECOG status 1 = 20.6%    (c) ECOG status 2 = 3.2%	BOLT exploratory analysis suggests prognostic [7]
Prior radiotherapy for BCC	Yes	Yes  (i) BOLT = 7.6%  (ii) ERIVANCE = 20.6% for target and 27.0% for current or prior	Chang et al. [25] suggest nonsignificant relationship with ORR
Prior systemic therapy for BCC	Yes	No  (i) BOLT = 6.1%  (ii) ERIVANCE = 11.1% (systematic or topical)	Chang et al. [25] suggest significant relationship with ORR
Prior surgery for BCC	Yes	Yes  (i) BOLT = 72.7%  (ii) ERIVANCE = 88.9%	Clinical advisors suggest highly prognostic in refractory population

BCC: basal cell carcinoma; ECOG: Eastern Cooperative Oncology Group; ORR: objective response rate. Note. BOLT summaries are based on the 200 mg full analysis set population [7]; ERIVANCE summaries are based on Sekulic et al. [8] and the European Medicines Agency assessment report [9].